These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15851915)

  • 21. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
    Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ
    J Infect Dis; 2008 Jul; 198(2):234-40. PubMed ID: 18540803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
    Boyd MA; Aarnoutse RE; Ruxrungtham K; Stek M; van Heeswijk RP; Lange JM; Cooper DA; Phanuphak P; Burger DM
    J Acquir Immune Defic Syndr; 2003 Oct; 34(2):134-9. PubMed ID: 14526202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
    Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
    Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
    Chadwick EG; Capparelli EV; Yogev R; Pinto JA; Robbins B; Rodman JH; Chen J; Palumbo P; Serchuck L; Smith E; Hughes M;
    AIDS; 2008 Jan; 22(2):249-55. PubMed ID: 18097227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
    Moltó J; Valle M; Blanco A; Negredo E; DelaVarga M; Miranda C; Miranda J; Domingo P; Vilaró J; Tural C; Costa J; Barbanoj MJ; Clotet B
    Clin Pharmacokinet; 2007; 46(1):85-92. PubMed ID: 17201460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
    Montaner JS; Schutz M; Schwartz R; Jayaweera DT; Burnside AF; Walmsley S; Saag MS
    MedGenMed; 2006 May; 8(2):36. PubMed ID: 16926775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
    van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
    Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.
    Chiu YL; Klein CE; Woodward WC; King KR; Naylor C; Awni W; Brun S
    AIDS Patient Care STDS; 2007 Apr; 21(4):247-51. PubMed ID: 17461719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.